Heterofused piperidines as orexin antagonists

Details Heterofused piperidines as orexin antagonists Heterofused piperidines as orexin antagonists

2008-03-27

2011-11-29

O Dell, David K (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S114000, C546S122000, C514S292000, C514S300000, C514S301000

Reexamination Certificate

active

08067598

ABSTRACT:
The present invention relates to compounds of formulawherein R1, R2, R3, and R4are as defined herein andhetaryl is a one or two ring-membered heteroaromatic ring system, connected to the carbon atoms of the piperidine group selected from the group consisting ofor to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders in which orexin pathways are involved, like sleep disorders.

REFERENCES:
patent: WO 2004/085403 (2004-10-01), None
patent: WO 2005/118548 (2005-12-01), None
patent: WO 2007/105177 (2007-09-01), None
patent: WO 2007/122591 (2007-11-01), None
Ernest L. Eliel “Infelicitous Stereochemical Nomenclature” CHIRALITY 1997, 9, 428-430.
Siegel, J. M., Annu. Rev. Psychol. vol. 55, pp. 125-148 (2004).
De Lecea et al., Proc. Natl. Acad. Sci. USA vol. 95, pp. 322-327 (1998).
Sakurai et al., Cell, vol. 92, pp. 573-585 (1998).
Sakurai, Regulatory Peptides, vol. 126 pp. 3-10 (2005).
Peyron et al., J. Neurosci. vol. 18, pp. 9996-10015 (1998).
Nambu et al., Brain Res. vol. 827, pp. 243-260 (1999).
Chemelli et al., Cell, vol. 98 pp. 437-451 (1999).
Lin et al., Cell, vol. 98, pp. 365-376 (1999).
Nishino et al., Lancet, vol. 355, pp. 39-40 (2000).
Peyron et al., Nature Medicine vol. 6, pp. 991-997 (2000).
Mignot et al., Sleep vol. 11, pp. 1012-1020 (1997).
Piper et al., Eur. J. Neuroscience vol. 12, pp. 726-730 (2000).
Sakamoto et al., Regul. Pept. vol. 118, pp. 183-191 (2004).
Ida et al., Biochem. Biophys. Res. Comm. vol. 270, pp. 318-323 (2000).
Kuru et al., Neuroreport vol. 11 pp. 1977-1980 (2000).
Winsky-Sommerer et al., J. Neuroscience vol. 24 pp. 11439-11448 (2004).
Chang et al., Neuroscience Research vol. 57, Issue 3, pp. 462-466 (2007).
Suzuki et al., Brain Research vol. 1044 pp. 116-121 (2005).
Digby et al, J. Endocrinol. vol. 191 pp. 129-136 (2006).
Cai et al., Expert Opin. Ther. Patents, vol. 16(5) pp. 631-646 (2006).
Bingham et al., Current Opin. in Drug Discovery & Development vol. 9(5) pp. 551-559 (2006).
Bourgin et al., J. Neurosci. vol. 20(20), pp. 7760-7765 (2000).
Smith et al., Neurosci. Lett. vol. 341(3) pp. 256-258 (2003).
Malherbe et al., Mol. Pharmacol. vol. 64 pp. 823-832 (2003).
Shiozawa et al., Chemical & Pharmaceutical Bulletin, vol. 32(7) pp. 2522-2529 (1984).
Iriarte et al., Journal of Heterocyclic Chemistry (1976) vol. 13(2) pp. 393-394.
Brisbare-Roch, C. et al,Nature Medicine, 12(2) (2007) 150-155 XP002483450.

Affiliated with

Also associated with

Rating

Heterofused piperidines as orexin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterofused piperidines as orexin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterofused piperidines as orexin antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4266000